Saturday 17 October 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,125.0%, EPS fell 66.7% and free cash flow fell 67.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
59.79
2.07
−3.35%
Follow CGON
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1,006.20 | 1,116.58 | 713.89 | 1,394.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(135.02) | (100.46) | (88.62) | (79.46) | |
P/B ratio |
6.09 | 5.24 | 4.26 | 4.49 | |
Price to Tangible BV |
6.15 | 5.29 | 4.33 | 4.59 | |
EV/Sales |
843.02 | 908.84 | 551.48 | 1,092.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(29.42) | (29.10) | (18.73) | (20.74) | |
EV/FCF |
(29.28) | (29.02) | (18.72) | (20.68) | |
Quick Ratio |
21.78 | 30.60 | 24.09 | 22.30 | |
Current Ratio |
22.22 | 31.30 | 24.63 | 22.79 | |
Net Debt/EBITDA |
11.76 | 16.80 | 15.76 | 12.86 | |
Debt/Assets |
0.28% | 0.26% | 0.38% | 0.41% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.00 | |
Operating CF/Net income |
0.59 | 0.95 | 0.88 | 0.89 | |
Capex/Depreciation |
0.57 | (0.12) | 0.00 | 0.06 | |
Research and Development Expense of Revenue |
4,724.03% | 4,037.86% | 1,290.22% | 1,673.71% | |
Selling, General and Administrative Expense of Revenue |
2,504.41% | 1,918.74% | 774.89% | 1,400.60% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
1,238.89% | 597.78% | 309.52% | 440.04% | |
Graham Net Nets |
0.16 | 0.19 | 0.22 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.79%) | (3.44%) | (4.99%) | (5.06%) | |
Free Cash Flow Yield |
(2.86%) | (2.80%) | (4.13%) | (3.79%) | |
Revenue per Share |
0.01 | 0.01 | 0.03 | 0.02 | |
Operating CF per Share |
(0.53) | (0.67) | (0.47) | (0.51) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.53) | (0.68) | (0.47) | (0.51) | |
Cash per Share |
11.66 | 12.73 | 9.60 | 8.87 | |
Shareholders Equity per Share |
11.67 | 12.92 | 9.74 | 8.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.67 | 12.92 | 9.74 | 8.96 | |
Free Cash Flow |
(46.88) | (57.25) | (36.22) | (38.99) | |
Working Capital |
1,002.41 | 1,066.93 | 728.64 | 665.26 | |
Capital Expenditures |
(0.47) | (0.30) | (0.01) | (0.10) | |
Net Current Asset Value |
993.11 | 1,058.66 | 720.49 | 653.52 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.40 | 0.28 | 0.00 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.49 | 0.81 | 0.73 | 0.33 | |
Average Payables |
9.93 | 7.48 | 6.12 | 6.63 | |
Average Assets |
893.55 | 931.72 | 773.19 | 641.19 | |
Average Common Equity |
849.74 | 898.27 | 742.99 | 612.21 |
Columns are period end dates